{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:34:02Z","timestamp":1791920042298,"version":"4.3.4"},"reference-count":97,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,9]],"date-time":"2018-04-09T00:00:00Z","timestamp":1523232000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Wellcome Trust Centre Award","award":["203134\/Z\/16\/Z"],"award-info":[{"award-number":["203134\/Z\/16\/Z"]}]},{"name":"Wellcome Trust Senior Investigator Award","award":["100320\/Z\/12\/Z"],"award-info":[{"award-number":["100320\/Z\/12\/Z"]}]},{"DOI":"10.13039\/501100000265","name":"UK Medical Research Council","doi-asserted-by":"crossref","award":["MR\/K000500\/1"],"award-info":[{"award-number":["MR\/K000500\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","cell.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Parasitology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.pt.2018.04.002","type":"journal-article","created":{"date-parts":[[2018,4,25]],"date-time":"2018-04-25T08:23:48Z","timestamp":1524644628000},"page":"481-492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":131,"title":["Melarsoprol Resistance in African Trypanosomiasis"],"prefix":"10.1016","volume":"34","author":[{"given":"Alan H.","family":"Fairlamb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pt.2018.04.002_bib0005","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/bmj.2.2746.353","article-title":"Address in pathology, on chemiotherapy: Delivered before the seventeenth international congress of medicine","volume":"2","author":"Ehrlich","year":"1913","journal-title":"Br. Med. J."},{"key":"10.1016\/j.pt.2018.04.002_bib0010","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/S0140-6736(17)31510-6","article-title":"Human African trypanosomiasis","volume":"390","author":"Buscher","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2018.04.002_bib0015","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/583262","article-title":"Overview of the diagnostic methods used in the field for human African trypanosomiasis: what could change in the next years?","volume":"2015","author":"Bonnet","year":"2015","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.pt.2018.04.002_bib0020","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0140-6736(09)60829-1","article-title":"Human African trypanosomiasis","volume":"375","author":"Brun","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2018.04.002_bib0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001691","article-title":"Untreated human infections by Trypanosoma brucei gambiense are not 100% fatal","author":"Jamonneau","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2018.04.002_bib0030","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.pt.2017.11.008","article-title":"Do cryptic reservoirs threaten Gambiense-sleeping sickness elimination?","volume":"34","author":"Buscher","year":"2018","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2018.04.002_bib0035","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006201.pub3","article-title":"Chemotherapy for second-stage human African trypanosomiasis","author":"Lutje","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pt.2018.04.002_bib0040","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(09)61117-X","article-title":"Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial","volume":"374","author":"Priotto","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2018.04.002_bib0045","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/bmj.s4-1.70.360-a","article-title":"Arsenic as a remedy for the tsetse bite","author":"Livingstone","year":"1858","journal-title":"Br. Med. J."},{"key":"10.1016\/j.pt.2018.04.002_bib0050","first-page":"785","article-title":"Recherches sur le traitement et le pr\u00e9vention du nagana","volume":"16","author":"Laveran","year":"1902","journal-title":"Annls Inst. Pasteur"},{"key":"10.1016\/j.pt.2018.04.002_bib0055","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/bmj.1.2403.152","article-title":"Professor Koch on sleeping sickness","volume":"1","author":"Anon","year":"1907","journal-title":"Br. Med. J."},{"key":"10.1016\/j.pt.2018.04.002_bib0060","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1084\/jem.30.5.411","article-title":"Chemotherapy of trypanosome and spirochete infections: Chemical series. I. N-phenylglycine amide-p-arsonic acid","volume":"30","author":"Jacobs","year":"1919","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.pt.2018.04.002_bib0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00034983.1959.11685892","article-title":"Some approaches to the development of chemotherapeutic compounds","volume":"53","author":"Friedheim","year":"1959","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"10.1016\/j.pt.2018.04.002_bib0070","series-title":"Metallotherapeutic Drugs & Metal-based Diagnostic Agents, The use of metals in medicine","first-page":"297","article-title":"33As Metallotherapeutic arsenic compounds","author":"Ho","year":"2005"},{"key":"10.1016\/j.pt.2018.04.002_bib0075","series-title":"The African Trypanosomiases","first-page":"125","article-title":"Review of chemotherapeutic and chemoprophylactic agents","author":"Williamson","year":"1970"},{"key":"10.1016\/j.pt.2018.04.002_bib0080","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/cncr.29852","article-title":"The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy","volume":"122","author":"Falchi","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.pt.2018.04.002_bib0085","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S0140-6736(00)02141-3","article-title":"Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial","volume":"355","author":"Burri","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2018.04.002_bib0090","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0140-6736(04)16940-7","article-title":"Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness","volume":"364","author":"Schmid","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2018.04.002_bib0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001695","article-title":"Safety and efficacy of the 10-day melarsoprol schedule for the treatment of second stage Rhodesiense sleeping sickness","volume":"6","author":"Kuepfer","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2018.04.002_bib0100","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1046\/j.1365-3156.1998.00327.x","article-title":"Discrepancy in plasma melarsoprol concentrations between HPLC and bioassay methods in patients with T. gambiense sleeping sickness indicates that melarsoprol is metabolized","volume":"3","author":"Bronner","year":"1998","journal-title":"Trop. Med. Int. Health"},{"key":"10.1016\/j.pt.2018.04.002_bib0105","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1067\/mcp.2000.105990","article-title":"Investigations of the metabolites of the trypanocidal drug melarsoprol","volume":"67","author":"Keiser","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.pt.2018.04.002_bib0110","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0006-2952(00)00263-X","article-title":"Role of glutathione in the biliary excretion of the arsenical drugs trimelarsan and melarsoprol","volume":"59","author":"Gregus","year":"2000","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.pt.2018.04.002_bib0115","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1476-5381.1959.tb00946.x","article-title":"Drug resistance in trapanososmes: cross-resistance analyses","volume":"14","author":"Williamson","year":"1959","journal-title":"Br. J. Pharmacol. Chemother."},{"key":"10.1016\/j.pt.2018.04.002_bib0120","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2990.1986.tb00682.x","article-title":"Human African trypanosomiasis (T. b. gambiense): a study of 16 fatal cases of sleeping sickness with some observations on acute reactive arsenical encephalopathy","volume":"12","author":"Adams","year":"1986","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.pt.2018.04.002_bib0125","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1046\/j.1365-3156.2001.00710.x","article-title":"Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis","volume":"6","author":"Blum","year":"2001","journal-title":"Trop. Med. Int. Health"},{"key":"10.1016\/j.pt.2018.04.002_bib0130","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s002800050998","article-title":"Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia","volume":"44","author":"Soignet","year":"1999","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.pt.2018.04.002_bib0135","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00280-013-2320-9","article-title":"A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours","volume":"72","author":"Horsley","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.pt.2018.04.002_bib0140","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.urolonc.2008.02.018","article-title":"Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma","volume":"26","author":"Lin","year":"2008","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.pt.2018.04.002_bib0145","first-page":"175","article-title":"Acute encephalopathy and arsenotherapy of syphilis","volume":"15","author":"McCann","year":"1946","journal-title":"Ulster Med. J."},{"key":"10.1016\/j.pt.2018.04.002_bib0150","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/j.1471-4159.2008.05706.x","article-title":"The blood\u2013brain barrier significantly limits eflornithine entry into Trypanosoma brucei brucei infected mouse brain","volume":"107","author":"Sanderson","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.pt.2018.04.002_bib0155","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/0035-9203(91)90032-T","article-title":"African trypanosomiasis and drug-induced encephalopathy: risk factors and pathogenesis","volume":"85","author":"Pepin","year":"1991","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2018.04.002_bib0160","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/S0140-6736(89)92340-4","article-title":"Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness","volume":"1","author":"Pepin","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2018.04.002_bib0165","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/0035-9203(95)90673-8","article-title":"Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness","volume":"89","author":"Pepin","year":"1995","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2018.04.002_bib0170","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/0035-9203(87)90211-2","article-title":"Melarsoprol and reactive encephalopathy in Trypanosoma brucei rhodesiense","volume":"81","author":"Arroz","year":"1987","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2018.04.002_bib0175","first-page":"72","article-title":"An evaluation of prednisolone as a routine adjunct to the treatment of T rhodesiense","volume":"78","author":"Foulkes","year":"1975","journal-title":"J. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2018.04.002_bib0180","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0022-3565(25)05655-1","article-title":"On the specificity of the so-called arsenic receptor in the higher animals","volume":"25","author":"Voegtlin","year":"1925","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pt.2018.04.002_bib0185","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1073\/pnas.86.8.2607","article-title":"Trypanothione is the primary target for arsenical drugs against African trypanosomes","volume":"86","author":"Fairlamb","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2018.04.002_bib0190","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1432-1033.1994.tb18740.x","article-title":"Mechanism of inhibition of trypanothione reductase and glutathione reductase by trivalent organic arsenicals","volume":"221","author":"Cunningham","year":"1994","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.pt.2018.04.002_bib0195","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nature10771","article-title":"High-throughput decoding of antitrypanosomal drug efficacy and resistance","volume":"482","author":"Alsford","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.pt.2018.04.002_bib0200","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1432-1033.1987.tb13563.x","article-title":"Effects of various metabolic conditions and of the trivalent arsenical melarsen oxide on the intracellular levels of fructose 2,6-bisphosphate and of glycolytic intermediates in Trypanosoma brucei","volume":"166","author":"Van Schaftingen","year":"1987","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.pt.2018.04.002_bib0205","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0014-4894(66)90009-9","article-title":"Analysis of the development of arsenical resistance in trypanosomes in vitro","volume":"18","author":"Hawking","year":"1966","journal-title":"Expl. Parasitol."},{"key":"10.1016\/j.pt.2018.04.002_bib0210","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/167147a0","article-title":"Acquired resistance to \u2018Melarsen\u2019, tryparsamide and amidines in pathogenic trypanosomes after treatment with \u2018Melarsen\u2019 alone","volume":"167","author":"Rollo","year":"1951","journal-title":"Nature"},{"key":"10.1016\/j.pt.2018.04.002_bib0215","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.ijpara.2007.05.007","article-title":"Melarsoprol- and pentamidine-resistant Trypanosoma brucei rhodesiense populations and their cross-resistance","volume":"37","author":"Bernhard","year":"2007","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.pt.2018.04.002_bib0220","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1124\/mol.106.031351","article-title":"Loss of the high-affinity pentamidine transporter is responsible for high levels of cross-resistance between arsenical and diamidine drugs in African trypanosomes","volume":"71","author":"Bridges","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.pt.2018.04.002_bib0225","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0014-4894(91)90138-M","article-title":"Differential sensitivity of Trypanosoma brucei rhodesiense isolates to in vitro lysis by arsenicals","volume":"72","author":"Yarlett","year":"1991","journal-title":"Expl. Parasitol."},{"key":"10.1016\/j.pt.2018.04.002_bib0230","doi-asserted-by":"crossref","first-page":"28153","DOI":"10.1074\/jbc.270.47.28153","article-title":"Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen-sensitive and -resistant Trypanosoma brucei brucei","volume":"270","author":"Carter","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pt.2018.04.002_bib0235","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0140-6736(05)66793-1","article-title":"Detection of arsenical drug resistance in Trypanosoma brucei with a simple fluorescence test","volume":"366","author":"Stewart","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2018.04.002_bib0240","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.molbiopara.2005.10.016","article-title":"The role of Trypanosoma brucei MRPA in melarsoprol susceptibility","volume":"146","author":"Alibu","year":"2006","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.pt.2018.04.002_bib0245","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/361173a0","article-title":"Arsenical-resistant trypanosomes lack an unusual adenosine transporter","volume":"361","author":"Carter","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.pt.2018.04.002_bib0250","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1126\/science.285.5425.242","article-title":"A nucleoside transporter from Trypanosoma brucei involved in drug resistance","volume":"285","author":"Maser","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.pt.2018.04.002_bib0255","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1128\/EC.2.5.1003-1008.2003","article-title":"Mechanisms of arsenical and diamidine uptake and resistance in Trypanosoma brucei","volume":"2","author":"Matovu","year":"2003","journal-title":"Eukaryot. Cell"},{"key":"10.1016\/j.pt.2018.04.002_bib0260","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1371\/journal.pntd.0000523","article-title":"Genotypic status of the TbAT1\/P2 adenosine transporter of Trypanosoma brucei gambiense isolates from Northwestern Uganda following melarsoprol withdrawal","volume":"3","author":"Kazibwe","year":"2009","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2018.04.002_bib0265","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.trstmh.2006.11.008","article-title":"Isolation and propagation of Trypanosoma brucei gambiense from sleeping sickness patients in south Sudan","volume":"101","author":"Maina","year":"2007","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2018.04.002_bib0270","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0166-6851(01)00332-2","article-title":"Genetic variants of the TbAT1 adenosine transporter from African trypanosomes in relapse infections following melarsoprol therapy","volume":"117","author":"Matovu","year":"2001","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.pt.2018.04.002_bib0275","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1242\/jcs.079467","article-title":"Aquaporins at a glance","volume":"124","author":"Verkman","year":"2011","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.pt.2018.04.002_bib0280","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1042\/BC20040095","article-title":"Aquaporins from pathogenic protozoan parasites: structure, function and potential for chemotherapy","volume":"97","author":"Beitz","year":"2005","journal-title":"Biol. Cell"},{"key":"10.1016\/j.pt.2018.04.002_bib0285","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1159\/000354490","article-title":"Trypanosoma brucei aquaglyceroporins facilitate the uptake of arsenite and antimonite in a pH dependent way","volume":"32","author":"Uzcategui","year":"2013","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.pt.2018.04.002_bib0290","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.12613","article-title":"Evolutionary genomics of epidemic visceral leishmaniasis in the Indian subcontinent","volume":"5","author":"Imamura","year":"2016","journal-title":"eLife"},{"key":"10.1016\/j.pt.2018.04.002_bib0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001227","article-title":"Visceral leishmaniasis and arsenic: an ancient poison contributing to antimonial treatment failure in the Indian subcontinent?","volume":"5","author":"Perry","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2018.04.002_bib0300","doi-asserted-by":"crossref","first-page":"19932","DOI":"10.1073\/pnas.1311535110","article-title":"Chronic exposure to arsenic in drinking water can lead to resistance to antimonial drugs in a mouse model of visceral leishmaniasis","volume":"110","author":"Perry","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2018.04.002_bib0305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003518","article-title":"Arsenic exposure and outcomes of antimonial treatment in visceral leishmaniasis patients in Bihar, India : a retrospective cohort study","volume":"9","author":"Perry","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2018.04.002_bib0310","doi-asserted-by":"crossref","first-page":"10996","DOI":"10.1073\/pnas.1202885109","article-title":"Aquaglyceroporin 2 controls susceptibility to melarsoprol and pentamidine in African trypanosomes","volume":"109","author":"Baker","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2018.04.002_bib0315","doi-asserted-by":"crossref","first-page":"42669","DOI":"10.1074\/jbc.M404518200","article-title":"Cloning, heterologous expression, and characterization of three aquaglyceroporins from Trypanosoma brucei","volume":"279","author":"Uzcategui","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pt.2018.04.002_bib0320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005436","article-title":"Pentamidine is not a permeant but a nanomolar inhibitor of the Trypanosoma brucei aquaglyceroporin-2","volume":"12","author":"Song","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.pt.2018.04.002_bib0325","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/jac\/dkt442","article-title":"Trypanosoma brucei aquaglyceroporin 2 is a high-affinity transporter for pentamidine and melaminophenyl arsenic drugs and the main genetic determinant of resistance to these drugs","volume":"69","author":"Munday","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.pt.2018.04.002_bib0330","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1007\/s00018-016-2173-6","article-title":"Comparative genomics of drug resistance in Trypanosoma brucei rhodesiense","volume":"73","author":"Graf","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.pt.2018.04.002_bib0335","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0001-706X(96)00131-3","article-title":"Characterisation of cloned lines of Trypanosoma brucei expressing stable resistance to MelCy and suramin","volume":"60","author":"Scott","year":"1996","journal-title":"Acta Trop."},{"key":"10.1016\/j.pt.2018.04.002_bib0340","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1046\/j.1365-3156.2001.00724.x","article-title":"The situation of sleeping sickness in Angola: a calamity","volume":"6","author":"Stanghellini","year":"2001","journal-title":"Trop. Med. Int. Health"},{"key":"10.1016\/j.pt.2018.04.002_bib0345","doi-asserted-by":"crossref","first-page":"966","DOI":"10.3201\/eid1406.071266","article-title":"High failure rates of melarsoprol for sleeping sickness, Democratic Republic of Congo","volume":"14","author":"Robays","year":"2008","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.pt.2018.04.002_bib0350","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1046\/j.1365-3156.2001.00714.x","article-title":"Re-emergence of epidemic sleeping sickness in southern Sudan","volume":"6","author":"Moore","year":"2001","journal-title":"Trop. Med. Int. Health"},{"key":"10.1016\/j.pt.2018.04.002_bib0355","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0035-9203(99)90151-7","article-title":"Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda","volume":"93","author":"Legros","year":"1999","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2018.04.002_bib0360","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1365-3156.2005.01545.x","article-title":"Drug-resistance of Trypanosoma b. rhodesiense isolates from Tanzania","volume":"11","author":"Kibona","year":"2006","journal-title":"Trop. Med. Int."},{"key":"10.1016\/j.pt.2018.04.002_bib0365","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003212","article-title":"Melarsoprol sensitivity profile of Trypanosoma brucei gambiense isolates from cured and relapsed sleeping sickness patients from the Democratic Republic of the Congo","volume":"8","author":"Pyana Pati","year":"2014","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2018.04.002_bib0370","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.meegid.2014.12.017","article-title":"Population genetics of Trypanosoma brucei gambiense in sleeping sickness patients with treatment failures in the focus of Mbuji-Mayi, Democratic Republic of the Congo","volume":"30","author":"Pyana","year":"2015","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.pt.2018.04.002_bib0375","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nrmicro3298","article-title":"The molecular arms race between African trypanosomes and humans","volume":"12","author":"Pays","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.pt.2018.04.002_bib0380","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001025","article-title":"Isolation of Trypanosoma brucei gambiense from cured and relapsed sleeping sickness patients and adaptation to laboratory mice","volume":"5","author":"Pyana","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2018.04.002_bib0385","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002475","article-title":"Aquaporin 2 mutations in Trypanosoma brucei gambiense field isolates correlate with decreased susceptibility to pentamidine and melarsoprol","volume":"7","author":"Graf","year":"2013","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2018.04.002_bib0390","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijpddr.2015.04.002","article-title":"Chimerization at the AQP2-AQP3 locus is the genetic basis of melarsoprol-pentamidine cross-resistance in clinical Trypanosoma brucei gambiense isolates","volume":"5","author":"Graf","year":"2015","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.pt.2018.04.002_bib0395","unstructured":"WHO Expert Committee on the Control and Surveillance of Human African Trypanosomiasis (2013) Control and Surveillance Of Human African trypanosomiasis: Report of a WHO Expert Committee. Tech. Report Series (World Health Organization) 984"},{"key":"10.1016\/j.pt.2018.04.002_bib0400","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1371\/journal.pctr.0010039","article-title":"Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda","volume":"1","author":"Priotto","year":"2006","journal-title":"PLoS Clin. Trials"},{"key":"10.1016\/j.pt.2018.04.002_bib0405","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006307","article-title":"Aquaglyceroporin-null trypanosomes display glycerol transport defects and respiratory-inhibitor sensitivity","volume":"13","author":"Jeacock","year":"2017","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.pt.2018.04.002_bib0410","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.parint.2005.09.003","article-title":"Chemotherapeutic efficacy of ascofuranone in Trypanosoma vivax-infected mice without glycerol","volume":"55","author":"Yabu","year":"2006","journal-title":"Parasitol. Int."},{"key":"10.1016\/j.pt.2018.04.002_bib0415","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijpddr.2013.01.004","article-title":"Functional expression of TcoAT1 reveals it to be a P1-type nucleoside transporter with no capacity for diminazene uptake","volume":"3","author":"Munday","year":"2013","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.pt.2018.04.002_bib0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2015.00032","article-title":"Transport proteins determine drug sensitivity and resistance in a protozoan parasite, Trypanosoma brucei","volume":"6","author":"Munday","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.pt.2018.04.002_bib0425","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001204","article-title":"A molecular mechanism for eflornithine resistance in African trypanosomes","volume":"6","author":"Vincent","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.pt.2018.04.002_bib0430","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.mib.2016.08.005","article-title":"Exploiting the Achilles\u2019 heel of membrane trafficking in trypanosomes","volume":"34","author":"Zoltner","year":"2016","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.pt.2018.04.002_bib0435","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004942","article-title":"Specific cell targeting therapy bypasses drug resistance mechanisms in African trypanosomiasis","volume":"11","author":"Unciti-Broceta","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.pt.2018.04.002_bib0440","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/mmi.12979","article-title":"Functional analysis of drug resistance-associated mutations in the Trypanosoma brucei adenosine transporter 1 (TbAT1) and the proposal of a structural model for the protein","volume":"96","author":"Munday","year":"2015","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.pt.2018.04.002_bib0445","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrmicro.2016.193","article-title":"Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need","volume":"15","author":"Field","year":"2017","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.pt.2018.04.002_bib0450","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0140-6736(17)32758-7","article-title":"Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial","volume":"391","author":"Mesu","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2018.04.002_bib0455","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1128\/AAC.00332-10","article-title":"Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis","volume":"54","author":"Sokolova","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2018.04.002_bib0460","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/jac\/dkv376","article-title":"Nitroheterocyclic drug resistance mechanisms in Trypanosoma brucei","volume":"71","author":"Wyllie","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.pt.2018.04.002_bib0465","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001151","article-title":"SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis","volume":"5","author":"Jacobs","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2018.04.002_bib0470","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.4155\/fmc.11.80","article-title":"Benzoxaboroles: a new class of potential drugs for human African trypanosomiasis","volume":"3","author":"Jacobs","year":"2011","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.pt.2018.04.002_bib0475","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004299","article-title":"Genomic and proteomic studies on the mode of action of oxaboroles against the African trypanosome","volume":"9","author":"Jones","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2018.04.002_bib0480","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.bmcl.2017.11.028","article-title":"Identification of a 4-fluorobenzyl l-valinate amide benzoxaborole (AN11736) as a potential development candidate for the treatment of Animal African Trypanosomiasis (AAT)","volume":"28","author":"Akama","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.pt.2018.04.002_bib0485","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nrmicro2221","article-title":"The trypanosome flagellar pocket","volume":"7","author":"Field","year":"2009","journal-title":"Nat. Rev. Microbiol."}],"container-title":["Trends in Parasitology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471492218300679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471492218300679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T18:53:12Z","timestamp":1751568792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471492218300679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":97,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1471492218300679"],"URL":"https:\/\/doi.org\/10.1016\/j.pt.2018.04.002","relation":{},"ISSN":["1471-4922"],"issn-type":[{"value":"1471-4922","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Melarsoprol Resistance in African Trypanosomiasis","name":"articletitle","label":"Article Title"},{"value":"Trends in Parasitology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pt.2018.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}